composed of the N-terminal part of ETV6 fused to the near complete RUNX1 protein.
Introduction
Acute Lymphoblastic Leukemia (ALL) is the most frequent pediatric cancer in children and accounts for ~25% of all pediatric cancers [1] . Precursor B cell ALL (pre-B ALL), the predominant form of childhood ALL, has been associated with many genetic abnormalities including chromosomal translocations [2] . The t (12;21) translocation is the most common genetic aberration in childhood pre-B ALL, occurring in 25% of pre-B ALL cases [2] . This translocation leads to the formation of the ETV6-RUNX1 chimera, an in-frame fusion of an ETV6 (erythroblast transformation-specific variant 6) allele with an allele of RUNX1 (runt-related transcription factor 1) [3, 4] . The expression of the ETV6-RUNX1chimera is under the control of the ETV6 promoter, which leads to the expression of a chimeric transcription factor
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that do not have LOH in the residual allele, suggesting that other mechanisms contribute to the ETV6 inactivation [21, 22] . Consistent with its tumor suppressor activity, overexpression of ETV6 in Ras-transformed fibroblasts inhibits cell growth and enhances apoptosis in vitro and suppresses tumor formation in nude mice [23] [24] [25] . Thus, the complete inactivation of ETV6 appears to be required for leukemogenesis [26] .
A complete understanding of the impact of the loss of ETV6 in the initiation and progression of leukemia requires the identification of its downstream target genes. Very few transcriptional targets of ETV6 are currently known: MCSFR (macrophage colony-stimulating factor receptor) [27] , GpIbα and GpIX (platelet glycoprotein Ib alpha chain and IX) [28] , stromelysin-1/MMP-3 (matrix metalloprotein-3) [23] and the anti-apoptotic protein BCL-X L [25] . Using a microarray-based approach, we had previously identified several putative ETV6-regulated genes, including SPHK1 (sphingosine kinase 1) and PTGER4 (prostaglandin E2 receptor EP4 subtype) [29] .
In the present study, we investigated ETV6-mediated transcriptional regulation on the proximal promoters of SPHK1 and PTGER4 using Chromatin Immunoprecipitation (ChIP) and gene reporter assays. We show that SSPHK1 and PTGER4 are direct ETV6 transcriptional targets with ETV6-mediated transcriptional regulation requiring consensus EBS in the proximal promoter region. Furthermore, functional studies revealed that deregulated expression of these novel ETV6 transcriptional targets in Reh, an ETV6-deficient t(12;21) pre-B leukemia cell line, play a role in the pathophysiology of childhood pre-B ALL. 
Materials and Methods

Cell culture
Constructs
SPHK1 and PTGER4 promoters were amplified by PCR (Platinum Taq, Invitrogen) and subcloned in the pGL3-basic vector (Promega) upstream of the Firefly luciferase gene. The proximal promoter region tested were as follows: SPHK1 promoter -858/+115 and PTGER4 promoter -855/+601 [ Figure 2A ]. Full-length ETV6 was subcloned downstream of the pcDNA3.1 vector's (Invitrogen) CMV promoter. Mutation of consensus EBS (GGAA→CCAA) was done using the Quick Change Multi-Site Directed Mutagenesis kit (Stratagene). The PNT and ETS domains of ETV6 were removed by restriction endonuclease after inserting, respectively, a PacI or KpnI restriction site at each end of the domain of ETV6 subcloned in pcDNA3.1. The pLKO.1 constructs harboring the SPHK1 shRNA and PTGER4 shRNA were purchased from Open Biosystems (RHS4533, RHS4533 and EHS1001-43247). The integrity of all constructs was verified by direct sequencing of both strands with the ABI 3730 automatic sequencer. Primers, shRNA and scrambled shRNA sequences are presented in Table 1 .
Gene reporter assays
HeLa and Jurkat cells were transfected using lipofectamine TM 2000 (Invitrogen) with a combination of constructs: promoter constructs in pGL3-basic vector (Promega), pRL-CMV vector 
Chromatin immunoprecipitation assays
HeLa cells with inducible ETV6-HA [29] were incubated for 48-hour with 2 μg/ml doxycycline and IM9 cells expressing a lentivirus harboring ETV6-HA (pLenti-ETV6-HA) were cross-linked with 1% formaldehyde for 10 minutes at room temperature, glycine stopped, lysed, and sonicated to obtain 200-1500bp DNA fragments. After immunoprecipitation with an antiHAantibody (Santa Cruz Biotechnology sc-7392), the precipitates were reverse cross-linked and treated with proteinase K. The purified endogenous DNA was analysed by quantitative real-time PCR. Experimental controls were selected according to a previous ChIP-chip experiment conducted by our group (unpublished data): Negative maps to an exon-intron junction region of the chromosome-associated protein D2 (NCAPD2), 14834 maps to the proximal promoter of the activator of basal transcription 1 (ABT1) gene and 10505 maps to the proximal promoter of the cAMP responsive element binding protein 1 (CREB1).
Lentiviral transduction 1 x 10
6 Reh cells were infected at a multiplicity of infection of 1 in RPMI-1640 10% FBS 8 μg/mL polybrene (Sigma-Aldrich). Forty-eight hours later 1 μg/μL puromycin (Sigma-Aldrich) was added to enrich for transduced cells.
Quantitative PCR and immunoblot
Quantitative real-time PCR of mRNA was done as previously described [29] . For Western blots, 15 x 10 6 Reh cells were homogenized in RIPA buffer and quantified using a Lowry assay (BioRad). Proteins were denatured in sample buffer with SDS (2%) and 2-mercaptoethanol (2 mM), separated on a 12% SDS-PAGE and electroblotted to a nitrocellulose membrane (Roche). Non-specific binding sites were blocked using skimmed milk followed by hybridization with the primary antibodies (SPHK1: Abcam ab-56414; PTGER4 and GAPDH: Santa Cruz Biotechnology sc-13602 and sc-31915, respectively) and the secondary antibodies (Santa Cruz Biotechnology sc-166574 or sc-48167). Enhanced chemiluminescence (Pierce) allowed protein detection and their subsequent quantification by densitometry (Adobe Photoshop 7.0.1).
Cell proliferation
Cell Proliferation Reagent WST-1 (Roche) and cell counting was used to study Reh cell proliferation. Reh cells were seeded at 0.4 x 10 5 cells/mL and grown for four days without renewaing the culture medium. Formazan dye absorbance was measured at 450 nm with a reference at 750 nm.
DNA damage-induced apoptosis and cell cycle
Reh cells were seeded at a density of 4 x 10 5 cells/mL in 24-well plates for 12 hours and treated with 2 μM camptothecin for 4 hours (Tocris Bioscience). Harvested cells were stained using the FITC AnnexinV/Dead Cell apoptosis kit (Invitrogen). Cell cycle analysis was done using the FITC BrdU Flow Kit (BD Pharmigen) where 4 x 10 5 Reh cells were synchronized for 24-hour by serum-starvation and cultured in RPMI 1640 10% FBS medium for another 24-hour. Stained cells were captured and analyzed using BD Biosciences FACS Aria and BD FACSDiva software, respectively.
Transmigration assays
Migration of Reh cells was performed for 2-hour in a ChemoTx ® 3.2 mm diameter 96 well-plate (NeuroProbe) with an input of 2 x 10 5 cells and CXCL12 as a chemoattractant (ProSpec). Cell quantification was done using the Cell Proliferation Reagent WST-1 (Roche) or by cell count using a Coulter counter (Beckman).
Clonogenic assays
After 2 weeks of selection with 1 μg/μL puromycin, 500 Reh cells infected with lentivirus were plated in quadruplicate in 1 ml of HSC-CFU Basic Human medium (Miltenyi Biotec inc) (1.2% methylcellulose, 30% FBS, 1% BSA, 0.1mM 2-mercaptoethanol, and 2mM L-glutamine) onto 35mm tissue culture dishes and incubated for 18 days in a humidified atmosphere at 37 o C and 5% CO 2 [52] . Colonies consisting of > 40 cells were counted using an inverted microscope.
Statistical analysis
Graphs and statistical analysis were done using the GraphPad 5.0 software. For all experiments, unless otherwise mentioned, statistical significance was indicated as follows: *: p ≤ 0.05, **: p ≤ 0.01, ***: p ≤ 0.001.
Results
ETV6 expression induces a tumor suppressor phenotype in lymphoblastic cells
ETV6 has previously been shown to have tumor suppressor capabilities in NIH-3T3 cells [23] [24] [25] . To determine whether ETV6 has tumor suppressor activity in human lymphoblastic cells, we overexpressed ETV6 via lentivirus infection in REH cells, with high levels of ETV6 protein in infected cells confirmed by Western blot [ Figure 1A , inset]. ETV6 overexpression reduced cell proliferation and clonogenic potential of Reh cells compared to mock infected cells [ Figure 1A , B], suggesting that loss of ETV6 can increase the proliferative capacity of t(12;21)-positive pre-B leukemia cells.
Etv6 mediates transcriptional repression of SPHK1 and ptger4 via its PNT and ETS functional domains
We have previously identified several genes that were deregulated early after ETV6-induced expression using microarray expression profiling [29] . Two of these genes, SPHK1 and PTGER4, were retained for further analysis. To examine whether ETV6 can bind to these promoters endogenously, we first conducted ChIP assays in HeLa cells overexpressing HA-Novel transcriptional targets of ETV6, a transcription factor frequently altered in childhood pre-B acute lymphoblastic leukemia tagged ETV6 (ETV6-HA). Quantitative PCR (qPCR) analysis indicated that there was significant enrichment of chromatinbound ETV6 to genomic fragments encompassing the proximal promoter regions of SPHK1 and PTGER4 [ Figure 2A ] in HeLa cells when using an antibody against HA compared to a non-specific control antibody [ Figure 2B ]. Similar ChIP results were obtained using the IM-9 B lymphoblastoid cell line for the promoters of SPHK1 and PTGER4 [ Figure 2C ]. These results indicate that ETV6 can form a chromatin complex on the promoters of its target genes.
To examine the ETV6-dependent modulation of these genes, we used gene reporter assays in HeLa and Jurkat, two highly transfectable cells lines, that were co-transfected with a pcDNA3.1 expression vector overexpressing wildtype ETV6 or versions lacking either the PNT domain, involved in proteinprotein interaction, or the ETS domain, required for DNA binding at the consensus EBS [ Figure 3A ]. An artificial promoter containing three consensus EBS located upstream of the thymidine kinase minimal promoter (EBS 3 tk) was used as control for ETV6-mediated transcriptional repression. Following ETV6 overexpression, the activity of EBS 3 tk was dramatically reduced in both HeLa and Jurkat cells [ Figure 3B ,C]. Previous studies on ETV6 transcriptional targets have shown that ETV6 requires the PNT and ETS functional domains to repress transcription [23, 25, 27, 28] , which we confirmed in our system in both cell lines [ Figure 3B , C].
To assess the ETV6-mediated transcriptional repression of the target genes, we subcloned a ~2 kb region of the SPHK1 and PTGER4 proximal promoters along with a region downstream of the transcription start site that contains putative EBS into the pGL3 reporter vector [ Figure 3A ]. Overexpression of ETV6 in both cell lines resulted in significant transcriptional repression of all reporter constructs [ Figure 3B , C], indicating that ETV6 can mediate transcriptional regulation of SPHK1 and PTGER4. Deletion of either PNT or ETS domain resulted in the loss of ETV6-mediated repression of these target genes in both cell lines [ Figure 3B , C]. These findings indicate that both ETS and PNT domains, through direct binding to the promoter and protein-protein interactions, respectively, are required for ETV6-mediated repressive function. [30] [31] [32] . Close examination of the SPHK1 and PTGER4 proximal promoter regions using the Transfac bioinformatics tool [33] predicted many consensus EBS. To delineate the minimal region of the proximal promoter required for ETV6-mediated repression, truncated versions of the SPHK1 and PTGER4 promoters [ Figure 2A ] were subcloned in the pGL3 reporter vector. Co-transfection of the various reporter constructs with ETV6 in both HeLa and Jurkat cell lines allowed us to identify these regions:-168/+115 for the SPHK1 promoter and -337/+178 for the PTGER4 promoter (data not shown). Changing EBS consensus sequences from GGAA/T to CCAA/T is sufficient to abolish their function [34] . Using sitedirected mutagenesis, we tested the ability of the various EBS to mediate ETV6-induced transcriptional repression in the minimal promoters of each gene. The SPHK1 minimal promoter has four putative consensus EBS: -158/-104/-84/+60. Mutation of any of these resulted in loss of ETV6-mediated repression in both HeLa and Jurkat cells [ Figure 4A , B]. The minimal PTGER4 promoter has six predicted consensus EBS: -305/-97/-92/-55/-49/+35. Because of the proximity of EBSs -97/-92 and of -55/-49, these pairs were mutated simultaneously. All EBS mutant constructs, with the exception of -305, abolished ETV6-dependant transcriptional repression [ Figure 4C , D]. These results indicate that ETV6 mediates transcriptional inhibition by binding to EBS in the proximal promoter region of both these genes.
ETV6 recognizes consensus EBS for transcriptional repression
Similar to other Ets family members such as ETS1 and FLI1, ETV6 mediates transcriptional regulation by binding to a consensus EBS
SPHK1 is a positive regulator of leukemic cell survival, proliferation, and migration
To assess the biological impact of ETV6 transcriptional targets, we knocked down their expression in the ETV6-deficient / t(12;21)-positive Reh cell line [35] and monitored cell proliferation, DNA damage-induced apoptosis, clonogenic potential, and cell migration. SPHK1 mRNA was reduced by ~40% by infecting Reh cells with lentiviruses expressing a shRNA targeting its sequence (shSPHK1, Figure 5A ). Western blot analysis confirmed this knockdown (data not shown). A scrambled sequence was used as a negative control (scSPHK1).
The proliferative properties of Reh cells were measured using the WST-1 colorimetric assay. SPHK1 knockdown resulted in a significantly slower proliferation of Reh cells, compared to control over a four day period (linear regression y intercept p=0.032) [ Figure 5B ]. However, downregulation of SPHK1 had no detectable impact on the cell-cycle distribution of a synchronized cell population 24 hours post-release (data not shown). These results are consistent with the well characterized role of the downstream effector of SPHK1, Sphingosine-1-Phosphate (S1P), on cell proliferation [36] . Indeed, higher levels of SPHK1 allow for more sphingosine to be converted into S1P via its lipid kinase activity, which results in enhanced cellular proliferation [37] . Sphingosine can also be transformed into pro-apoptotic ceramide via ceramide synthase [38] . Thus, SPHK1 levels are believed to act as a survival rheostat that balances the cellular level of the pro-apoptotic ceramide with the anti-apoptotic, pro-proliferation S1P signal. The role of SPHK1 on apoptotic pathways was therefore examined in Reh cells treated with camptothecin, a DNA damaging agent inhibiting the DNA repair ability of the DNA topoisomerase I. Downregulation of SPHK1 increased the sensitivity of Reh cells to camptothecin-induced apoptosis [ Figure 5C ].
The clonogenic potential of leukemic cell lines kept in suspension culture is reflected in the proportion of cells capable of maintaining in vitro cell growth. Indeed, the higher the clonogenic potential of a cell line, the higher the number of cells capable of autonomous cell growth. To examine the role of SPHK1 on the clonogenic potential of Reh cells colony formation in Figure 5D ]. Finally, we assessed the role of SPHK1 on the migration potential of leukemic cellsusing the CXCL12 chemoattractant in a transmigration assay. CXCL12 is the ligand for CXCR4, a G-protein coupled receptor expressed in pre-B leukemic cell lines [39] . SPHK1 downregulation reduced the migration potential of Reh cells at low CXCL12 concentration [ Figure 5E ], indicating that higher expression of SPHK1 can be favourable to the mobilisation of leukemic progenitors.
Novel transcriptional targets of ETV6, a transcription factor frequently altered in childhood pre-B acute lymphoblastic leukemia
These results indicate SPHK1 is an important regulator of cell survival, proliferation, and migration in leukemic cells and suggest that ETV6, by repressing its expression, acts as a tumor repressor.
PTGER4 expression promotes leukemogenesis
PTGER4 is a G-protein coupled receptor responding to its ligand prostaglandin E2 (PGE2). To assess the functional role of PTGER4 during leukemogenesis its expression was knocked down by ~65-70% using shRNA infection, as detailed above [ Figure 6A ]. Western blot analysis confirmed this knockdown (data not shown). PTGER4 downregulation, with both shRNAs, led to a significant decrease in clonogenic capacity and proliferation rate of Reh cells [ Figure 6B ], D but did not affect the cell cycle distribution of synchronized Reh cells over a 24-hour period (data not shown). Furthermore, PTGER4 repression inhibited CXCL12-induced migration Figure 6E . Interestingly, it had no effect on camptophecin-induced apoptosis [ Figure 6C ]. These data were confirmed by specifically inhibiting PTGER4 with the L-161,982 antagonist, which prevents PTGER4-mediated signaling [40] . Consistent dose-dependent growth inhibition was observed in the presence of PTGER4 inhibitor [ Figure 7A ], confirming that PTGER4 signaling plays a positive role in Reh cell proliferation. Cell migration was also inhibited in a dose-dependent manner with the addition of increasing concentrations of L-161,982 [ Figure 7B ]. Camptothecin-induced apoptosis was unaffected by PTGER4 chemical inhibition [ Figure 7C ], confirming the results obtained using shRNA knockdown. These results indicate that PTGER4 transduces a positive leukemic signal enhancing cell proliferation and migration in REH cells.
Discussion
Several childhood pre-B ALL harbor the t(12;21) translocation, yielding an ETV6-RUNX1 fusion protein thought to confer ETV6-dependant repressive activity to RUNX1 transcriptional targets [18] . Experimental evidence indicates that the ETV6-RUNX1 fusion is insufficient to initiate leukemia, which instead requires the allelic loss of the remaining wildtype ETV6 allele, suggesting that the deregulation of ETV6 transcriptional targets play an important role in leukemogenesis. However, functional targets of ETV6 involved in leukemogenesis remain elusive. Using a combination of ChIP, gene reporter assays, and loss-of-function analyses we demonstrated that SPHK1 and PTGER4 are direct transcriptional targets of ETV6 and that they have a functional role in promoting or maintaining a leukemic phenotype. Although increased expression of both these genes has been associated with many types of cancer, this is the first Figure 5 : The ETV6-transcriptional target SPHK1 is a positive regulator of leukemia cell survival, clonogenic potential, and migration. (A) qPCR analysis of SPHK1 expression in Reh cells stably expressing a SPHK1-specific shRNA (shSPHK1) or a scrambled shRNA (scSPHK1). Expression levels were normalized to GAPDH and expressed relative to sc-SPHK1-expressing cells. Western blot analysis of SPHK1 protein levels confirms the knockdown of the endogenous protein (data not shown).
(B) Knockdown of SPHK1 expression decreases Reh cell proliferation. Formazan dye absorbance is proportional to cell density (mean ± SE). Statistical significance of differences between the linear regression slopes (*)(days 0 to 4) were assessed, using scSPHK1 as reference (n = 4). (C) SPHK1 is a negative regulator of DNA damage-induced apoptosis in Reh cells. The percent of apoptotic cells was determined by adding the fractions that were Annexin V + / PI + and Annexin V + /PI -gated outside the cellular debris (mean ± SE). Statistical significance was assessed using an unpaired t-test (n = 3). (D) Knockdown of SPHK1 expression decreases the clonogenic potential of Reh cells. The clonogenic surviving fraction corresponds to the plating efficiency of shSPHK1-infected cell normalized to the plating efficiency of the scSPHK1-infected Reh cells (expressed in percentage). (E) Knockdown of SPHK1 expression decreases transmigration potential of Reh cells. Relative cell migration is measured as the ratio of migrated cells/input (mean ± SE). Statistical significance was assessed using a non-parametric Mann-Whitney t-test (n = 4). demonstration that their expression could be modulated by the ETV6 tumor suppressor.
ETV6 binds directly to the promoter of SPHK1 and PTGER4
ETV6 can both interact directly with the histone deacetylase co-repressor complex SMRT/N-CoR/mSin3A/HDAC and bind DNA in a sequence-specific manner [10] [11] [12] [13] . Using ChIP analysis, we have shown that ETV6 can bind the promoter region of SPHK1 and PTGER4 loci. The molecular mechanisms used by ETV6 to Novel transcriptional targets of ETV6, a transcription factor frequently altered in childhood pre-B acute lymphoblastic leukemia regulate transcription require both its PNT protein-protein interaction domain and its ETS DNA-binding domain. In this study, we have shown that the overexpression of ETV6 in two different cell lines can actively repress the proximal promoterregion of both SPHK1 and PTGER4. This repression was dependent on both ETV6 functional domains, indicating that these genes behave like typical ETV6 transcriptional targets. Mutational analysis of the EBS on the minimal promoter region still responsive to ETV6 revealed that they were required for ETV6-mediated repression. Taken together these data strongly suggest that ETV6 binds directly to the promoter of these target genes to downregulate their expression.
A functional role of SPHK1 in the progression of ETV6-deficient pre-B ALL
Since the reporter assays revealed that the promoters of both target genes could be repressed by ETV6, our functional studies were conducted in the ETV6-deficient pre-B ALL Reh cell line. We found that the downregulation of SPHK1expression reduced cellular proliferation and migration andenhancedapoptosis in response to DNA damage. SPHK1 is a lipid kinase that catalyzes the phosphorylation of sphingosine to S1P, which in turn stimulates cell proliferation, survival and migration by binding to various S1P receptors (S1PR) [38] . S1PRs activate G proteins which interact with numerous intracellular pathways including MAPK/ERKs and PI3K, involved in cell proliferation Novel transcriptional targets of ETV6, a transcription factor frequently altered in childhood pre-B acute lymphoblastic leukemia and survival, as well as with PLC and Rac, both involved in cell migration. Sphingosine can also be transformed into ceramide, a pro-apoptotic signal, by ceramide synthase. Increased expression of SPHK1 would therefore shift sphingosine towards S1P rather than ceramide and would consequently favor cellular proliferation, survival, and migration. Our results are consistent with the known biological function of SPHK1 and attribute a functional role to SPHK1 in the progression of ETV6-deficient pre-B ALL. We have also observed that downregulation of SPHK1 results in decreased clonogenic potential of Reh cells, suggesting SPHK1 levels regulate autonomous cell growth, which would also contribute to leukemogenesis.
Leukemia can originate from a blockage of differentiation process in early progenitors and a premature mobilization of these defective progenitors in the circulation (egress). Gradients of S1P are directly involved in hematopoietic stem cell (HSC)/ progenitor cell (HPC) egress. High concentration of S1P in the peripheral blood and low levels of S1P in the bone marrow and other tissues promote the mobilization of HPC into the circulation [41, 42] . Recently, crosstalk has been uncovered between CXCR4/ CXCL12 pathway, responsible for the homing of the HPC to the bone marrow, and the S1P signaling pathway [43] . Increased levels of S1P activate there lease of the CXCL12 ligand from the bone marrow stroma tothe circulation and work in concert with S1P gradients to promote HPC egress from the bone marrow. Therefore, it is conceivable that increase of SPHK1 expression in ETV6-deficient ALL progenitors would favor their release from the bone marrow which, combined with the enhanced selfrenewal potential and the increase in proliferation, migration, and survival signals, would contribute to leukemogenesis.
Our findings are consistent with previous observations documenting the up-regulation of SPHK1 in many cancers, including acute leukemia [38] . Moreover, although the expression of SPHK1 has been shown to be regulated by a range of growth factors and protein kinases, this study provides the first evidence of SPHK1 regulation by a transcriptional repressor involved in childhood leukemia.
A functional role of PTGER4 in the progression of ETV6-deficient pre-B ALL
PTGER4 expression is elevated in numerous cancers including breast, colon, and endometrial adenocarcinoma and is known to enhance cell survival and cell proliferation by activating PKB(Akt), ERK1/2, and early growth response factor-1 (EGR-1) [44] [45] [46] [47] . PTGER4 is one of four PGE2 receptors, which in turn is synthesized by COX enzymes [47] . Overexpression of COX2 has a main role in the tumorigenesis of breast and colorectal cancer [48, 49] , and has been the target in several therapeutic approaches using nonsteroidal anti-inflammatory drugs (NSAIDs) similar to aspirin [50] . Because of side effects related to the use of NSAIDS, mostly affecting the heart, PTGER4 inhibitors have gained increasing attention. In this study, we have demonstrated that ETV6 directly binds to the PTGER4 promoter and represses its expression. Down-regulation of PTGER4 activity by shRNA or receptor antagonists in an ETV6-deficient cell line resulted in decreased proliferation, migration, and clonogenic potential, indicating that the increased expression of PTGER4 could contribute to leukemogenesis. These results indicate that the PGE2/PTGER4 pathway is involved in leukemogenic transformation and that increased PTGER4 receptor levels are sufficient to sensitize cells to transforming processes.
A recent study has uncovered a pivotal role for PGE2/PTGER4 signaling in HSC egress from the bone marrow. While the inhibition of PGE2/PTGER4 signaling in the stromal microenvironment causes HSC egress, inhibition of the PGE2/PTGER4 signaling within the hematopoietic cells favors myeloid hematopoietic progenitor cell, but not HSC, egress from the bone marrow [51] . It is difficult to consolidate these results with enhanced PGE2/ PTGER4 signaling in leukemic cells since it would favor homing of progenitor cells to the marrow. However, the role of PGE2/ PTGER4 in pre-B lymphoid cells was not assessed in that study and repression of this pathway in the bone marrow stroma in pre-B ALL has never been investigated. It is noteworthy that murine ETV6 hematopoietic cells are defective in homing to the bone marrow of transplanted mice [8] , suggesting that ETV6-deficient tumor precursor cells could egress rather than enter the bone marrow. The role of PTGER4 in the egress of these ETV6-deficient tumor precursor cells remains to be examined.
Overall, this study provides evidence that deregulated expression of ETV6 transcriptional targets following the loss of ETV6 might be involved in the development of childhood pre-B ALL. Further evidence assessing the impact of PTGER4 and SPHK1 dysregulation in patients that lack functional ETV6 could provide further insights into the mechanisms underlying ETV6-mediated leukemogenesis. Furthermore, inhibition of the PGE2/PTGER4 pathway or S1P production could provide interesting avenues for the development of alternative therapeutic approaches.
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